TrialJAMA oncology2016
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
William N William et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
80 papers cite itlatest 60 shown
this papertrialcites it